Zacks Research Upgrades Prestige Consumer Healthcare (NYSE:PBH) to Hold

Prestige Consumer Healthcare (NYSE:PBH) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued on Monday,Zacks.com reports.

Several other equities analysts have also commented on PBH. Oppenheimer lowered Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Weiss Ratings cut shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, June 25th. Finally, Canaccord Genuity Group reduced their price target on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a report on Friday, May 15th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Prestige Consumer Healthcare has an average rating of “Hold” and a consensus price target of $70.75.

Prestige Consumer Healthcare Stock Up 1.1%

Shares of NYSE PBH opened at $53.57 on Monday. Prestige Consumer Healthcare has a 52-week low of $42.62 and a 52-week high of $71.07. The firm has a market capitalization of $2.54 billion, a price-to-earnings ratio of 15.00, a PEG ratio of 1.66 and a beta of 0.34. The stock has a 50 day moving average price of $49.11 and a 200 day moving average price of $55.82. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.99 and a current ratio of 3.23.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.89 by $0.09. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The company had revenue of $265.71 million for the quarter, compared to the consensus estimate of $253.02 million. During the same period last year, the business posted $0.90 EPS. Prestige Consumer Healthcare’s quarterly revenue was up 6.5% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Sell-side analysts expect that Prestige Consumer Healthcare will post 4.55 earnings per share for the current year.

Institutional Investors Weigh In On Prestige Consumer Healthcare

A number of institutional investors have recently added to or reduced their stakes in PBH. UMB Bank n.a. grew its stake in Prestige Consumer Healthcare by 110.1% in the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after purchasing an additional 219 shares during the last quarter. Bayforest Capital Ltd purchased a new stake in shares of Prestige Consumer Healthcare during the fourth quarter valued at about $29,000. Geneos Wealth Management Inc. lifted its position in shares of Prestige Consumer Healthcare by 92.8% during the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after buying an additional 269 shares during the last quarter. Torren Management LLC bought a new stake in shares of Prestige Consumer Healthcare in the 4th quarter valued at about $35,000. Finally, Caitong International Asset Management Co. Ltd grew its position in shares of Prestige Consumer Healthcare by 69.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock worth $35,000 after buying an additional 236 shares during the last quarter. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).